EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Skeletal Senescence with Aging and Type 2 Diabetes

Joshua Nicholas Farr

Endocrinology and Metabolism · 2023

DOI: 10.3803/enm.2023.1727 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology and Metabolism, 2023. Verfasst von Joshua Nicholas Farr. Beteiligte Einrichtung: Robert and Arlene Kogod Center on Aging, Mayo Clinic College of Medicine, Rochester, MN, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Osteoporosis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoporosis and type 2 diabetes (T2D) are common diseases that often coexist. While both of these diseases are associated with poor bone quality and increased fracture risk, their pathogenesis of increased fracture risk differs and is multifactorial. Mounting evidence now indicates that key fundamental mechanisms that are central to both aging and energy metabolism exist. Importantly, these mechanisms represent potentially modifiable therapeutic targets for interventions that could prevent or alleviate multiple complications of osteoporosis and T2D, including poor bone quality. One such mechanism that has gained increasing momentum is senescence, which is a cell fate that contributes to multiple chronic diseases. Accumulating evidence has established that numerous boneresident cell types become susceptible to cellular senescence with old age. Recent work also demonstrates that T2D causes the premature accumulation of senescent osteocytes during young adulthood, at least in mice, although it remains to be seen which other bone-resident cell types become senescent with T2D. Given that therapeutically removing senescent cells can alleviate age-related bone loss and T2D-induced metabolic dysfunction, it will be important in future studies to rigorously test whether interventions that eliminate senescent cells can also alleviate skeletal dysfunction in context of T2D, as it does with aging.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2OsteoporosisMiceAnimalsAgingCellular SenescenceBone and Bones

Stichwörter der Autor:innen

AgingCellular senescenceDiabetes mellitus, type 2FractureOsteoporosis

Autor:innen und Institutionen

  • Robert and Arlene Kogod Center on Aging, Mayo Clinic College of Medicine, Rochester, MN, USA.
  • Division of Endocrinology, Mayo Clinic College of Medicine, Rochester, MN, USA.
  • Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, Rochester, MN, USA.

Förderung

  • NIDDK NIH HHS
  • NIH HHS
  • NIA NIH HHS
  • National Institutes of Health

Zitieren

APA

Farr, J. N. (2023). Skeletal Senescence with Aging and Type 2 Diabetes. Endocrinology and Metabolism. https://doi.org/10.3803/enm.2023.1727

Vancouver

Farr JN. Skeletal Senescence with Aging and Type 2 Diabetes. Endocrinology and Metabolism. 2023. doi:10.3803/enm.2023.1727

BibTeX
@article{Farr2023,
  author = {Farr, Joshua Nicholas},
  title = {Skeletal Senescence with Aging and Type 2 Diabetes},
  journal = {Endocrinology and Metabolism},
  year = {2023},
  doi = {10.3803/enm.2023.1727}
}
Kostenlos starten →